These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32246379)

  • 1. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
    Hirai T; Nemoto A; Ito Y; Matsuura M
    Breast Cancer Res Treat; 2020 May; 181(1):189-198. PubMed ID: 32246379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
    Adunlin G; Cyrus JW; Dranitsaris G
    Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: Meta-analyses of published studies.
    Kundu MG; Acharyya S
    Contemp Clin Trials; 2017 Feb; 53():20-28. PubMed ID: 27940185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival as a surrogate endpoint in advanced breast cancer.
    Miksad RA; Zietemann V; Gothe R; Schwarzer R; Conrads-Frank A; Schnell-Inderst P; Stollenwerk B; Siebert U
    Int J Technol Assess Health Care; 2008; 24(4):371-83. PubMed ID: 18828930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.
    Cartier S; Zhang B; Rosen VM; Zarotsky V; Bartlett JB; Mukhopadhyay P; Wagner S; Davis C
    Oncol Res Treat; 2015; 38(3):88-94. PubMed ID: 25792079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
    Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
    Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
    He Q; Li Q; Lv F; Kaitin KI; Shao L
    Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
    Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Lux MP; Böhme S; Hücherig S; Jeratsch U; Kürschner N; Lüftner D
    Breast Cancer Res Treat; 2019 Aug; 176(3):495-506. PubMed ID: 31065873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma.
    Nakashima K; Horita N; Nagai K; Manabe S; Murakami S; Ota E; Kaneko T
    J Thorac Oncol; 2016 Sep; 11(9):1574-85. PubMed ID: 27178983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
    Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of biological agents in metastatic triple-negative breast cancer.
    Bramati A; Girelli S; Torri V; Farina G; Galfrascoli E; Piva S; Moretti A; Dazzani MC; Sburlati P; La Verde NM
    Cancer Treat Rev; 2014 Jun; 40(5):605-13. PubMed ID: 24529896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
    Han K; Ren M; Wick W; Abrey L; Das A; Jin J; Reardon DA
    Neuro Oncol; 2014 May; 16(5):696-706. PubMed ID: 24335699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.